Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IVANASDAQ:ONCYNASDAQ:VYGRNASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIVAInventiva$3.11-7.7%$3.27$1.53▼$4.05$163.20M0.863,046 shs28,404 shsONCYOncolytics Biotech$0.47-6.5%$0.56$0.46▼$1.53$40.41M1528,843 shs928,687 shsVYGRVoyager Therapeutics$3.30+0.6%$3.43$2.75▼$9.55$182.61M0.95443,659 shs365,716 shsYMABY-mAbs Therapeutics$4.10+6.2%$4.47$3.55▼$16.11$185.64M0.53315,698 shs227,355 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIVAInventiva-3.71%-4.80%-0.88%+36.44%-8.92%ONCYOncolytics Biotech-3.42%-7.18%-12.63%-34.79%-56.87%VYGRVoyager Therapeutics+2.82%-4.51%+2.18%-22.46%-61.73%YMABY-mAbs Therapeutics+6.04%-4.69%-27.85%-38.14%-68.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIVAInventiva2.2445 of 5 stars3.42.00.00.02.71.70.6ONCYOncolytics Biotech2.1359 of 5 stars3.54.00.00.02.90.00.0VYGRVoyager Therapeutics4.6318 of 5 stars4.61.00.04.62.01.71.9YMABY-mAbs Therapeutics3.9854 of 5 stars4.43.00.00.03.04.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIVAInventiva 2.80Moderate Buy$10.40234.41% UpsideONCYOncolytics Biotech 2.75Moderate Buy$4.33826.72% UpsideVYGRVoyager Therapeutics 3.13Buy$13.39305.76% UpsideYMABY-mAbs Therapeutics 2.82Moderate Buy$16.70307.32% UpsideCurrent Analyst Ratings BreakdownLatest ONCY, VYGR, YMAB, and IVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ONCYOncolytics BiotechJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/14/2025YMABY-mAbs TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.005/14/2025YMABY-mAbs TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.004/22/2025YMABY-mAbs TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.004/8/2025VYGRVoyager TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/4/2025IVAInventivaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $9.003/28/2025IVAInventivaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.003/21/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $12.003/13/2025VYGRVoyager TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.003/13/2025VYGRVoyager TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/12/2025VYGRVoyager TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$12.00 ➝ $10.00(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIVAInventiva$9.20M17.74N/AN/A($0.67) per share-4.64ONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/AVYGRVoyager Therapeutics$66.96M2.73$2.34 per share1.41$5.37 per share0.61YMABY-mAbs Therapeutics$87.69M2.12N/AN/A$2.32 per share1.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIVAInventiva-$119.51MN/A0.00N/AN/AN/AN/AN/AN/AONCYOncolytics Biotech-$20.56M-$0.30N/AN/AN/AN/A-141.15%-84.73%7/30/2025 (Estimated)VYGRVoyager Therapeutics$132.33M-$1.464.65N/AN/A15.80%8.33%6.15%N/AYMABY-mAbs Therapeutics-$21.43M-$0.67N/AN/AN/A-28.22%-24.61%-18.49%N/ALatest ONCY, VYGR, YMAB, and IVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ONCYOncolytics Biotech-$0.09-$0.06+$0.03-$0.06N/AN/A5/13/2025Q1 2025YMABY-mAbs Therapeutics-$0.22-$0.12+$0.10-$0.12$19.97 million$20.90 million5/6/2025Q1 2025VYGRVoyager Therapeutics-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 million3/11/2025Q4 2024VYGRVoyager Therapeutics-$0.35-$0.59-$0.24-$0.59$16.58 million$4.39 million3/4/2025Q4 2024YMABY-mAbs Therapeutics-$0.13-$0.15-$0.02-$0.15$26.70 million$26.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIVAInventivaN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIVAInventivaN/A0.590.59ONCYOncolytics BiotechN/A2.992.99VYGRVoyager TherapeuticsN/A8.458.45YMABY-mAbs TherapeuticsN/A3.923.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIVAInventiva19.06%ONCYOncolytics Biotech6.82%VYGRVoyager Therapeutics48.03%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipIVAInventiva32.00%ONCYOncolytics Biotech0.10%VYGRVoyager Therapeutics6.39%YMABY-mAbs Therapeutics22.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIVAInventiva10052.48 million35.68 millionNot OptionableONCYOncolytics Biotech3086.42 million85.42 millionNot OptionableVYGRVoyager Therapeutics10055.34 million52.15 millionOptionableYMABY-mAbs Therapeutics15045.28 million34.71 millionOptionableONCY, VYGR, YMAB, and IVA HeadlinesRecent News About These CompaniesParadigm Biocapital Advisors LP Grows Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 16 at 8:35 AM | marketbeat.comOppenheimer Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $20.00May 16 at 2:05 AM | americanbankingnews.comY-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and ChallengesMay 14 at 3:18 AM | finance.yahoo.comY-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsMay 13 at 10:11 PM | finanznachrichten.deY-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call TranscriptMay 13 at 1:35 PM | seekingalpha.comY-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue EstimatesMay 13 at 8:45 AM | zacks.comY-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025May 13 at 7:05 AM | globenewswire.comY-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsMay 13 at 6:35 AM | globenewswire.comY-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)May 7, 2025 | globenewswire.comWhy Y-mAbs Therapeutics, Inc.’s (YMAB) Stock Is Down 5.65%May 6, 2025 | aaii.comY-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025May 6, 2025 | globenewswire.comShort Interest in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Drops By 16.1%May 5, 2025 | marketbeat.com2,861,825 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Acquired by Acorn Capital Advisors LLCMay 4, 2025 | marketbeat.comCaligan Partners LP Has $13.84 Million Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 3, 2025 | marketbeat.comRenaissance Technologies LLC Raises Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)May 3, 2025 | marketbeat.comY-mAbs Therapeutics (YMAB) Projected to Post Earnings on TuesdayMay 1, 2025 | marketbeat.comJPMorgan Chase & Co. Raises Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)April 30, 2025 | marketbeat.comEarnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to DeclineApril 29, 2025 | zacks.comBoothbay Fund Management LLC Buys 136,264 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)April 29, 2025 | marketbeat.comY-mAbs Therapeutics announces presentation of PK data of CD38-SADAApril 28, 2025 | markets.businessinsider.comY-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measuresApril 27, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCY, VYGR, YMAB, and IVA Company DescriptionsInventiva NASDAQ:IVA$3.18 -0.19 (-5.64%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Oncolytics Biotech NASDAQ:ONCY$0.47 -0.03 (-6.54%) Closing price 04:00 PM EasternExtended Trading$0.47 +0.00 (+0.09%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Voyager Therapeutics NASDAQ:VYGR$3.30 +0.02 (+0.61%) Closing price 04:00 PM EasternExtended Trading$3.39 +0.09 (+2.73%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.Y-mAbs Therapeutics NASDAQ:YMAB$4.10 +0.24 (+6.22%) Closing price 04:00 PM EasternExtended Trading$4.11 +0.01 (+0.24%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
